Thyroid Imaging Reporting and Data System Score Combined with the New Italian Classification for Thyroid Cytology Improves the Clinical Management of Indeterminate Nodules

• Main Authors: Salvatore Ulisse, Daniela Bosco, Francesco Nardi, Angela Nesca, Eleonora D’Armiento, Valeria Guglielmino, Corrado De Vito, Salvatore Sorrenti, Daniele Pironi, Francesco Tartaglia, Stefano Arcieri, Antonio Catania, Massimo Monti, Angelo Filippini, Valeria Ascoli
• Format: Article
• Language: English
• Published: Hindawi Limited 2017-01-01
• Series: International Journal of Endocrinology
• Online Access: http://dx.doi.org/10.1155/2017/9692304
• ISSN: 1687-8337; 1687-8345

The new Italian cytological classification (2014) of thyroid nodules replaced the TIR3 category of the old classification (2007) with two subclasses, TIR3A and TIR3B, with the aim of reducing the rate of surgery for benign diseases. Moreover, thyroid imaging reporting and data system (TI-RADS) score appears to ameliorate the stratification of the malignancy risk. We evaluated whether the new Italian classification has improved diagnostic accuracy and whether its association with TI-RADS score could improve malignancy prediction. We retrospectively analyzed 70 nodules from 70 patients classified as TIR3 according to the old Italian classification who underwent surgery for histological diagnosis. Of these, 51 were available for cytological revision according to the new Italian cytological classification. Risk of malignancy was determined for TIR3A and TIR3B, TI-RADS score, and their combination. A different rate of malignancy (p=0.0286) between TIR3A (13.04%) and TIR3B (44.44%) was observed. Also TI-RADS score is significantly (p=0.003) associated with malignancy. By combining cytology and TI-RADS score, patients could be divided into three groups with low (8.3%), intermediate (21.4%), and high (80%) risk of malignancy. In conclusion, the new Italian cytological classification has an improved diagnostic accuracy. Interestingly, the combination of cytology and TI-RADS score offers a better stratification of the malignancy risk.